Literature DB >> 7878631

Antithrombin III: associations with age, race, sex and cardiovascular disease risk factors. The Atherosclerosis Risk in Communities (ARIC) Study Investigators.

M G Conlan1, A R Folsom, A Finch, C E Davis, G Marcucci, P Sorlie, K K Wu.   

Abstract

Antithrombin III (AT III) is a major inhibitor of blood coagulation, and hereditary deficiency is associated with venous thrombotic disease. The Atherosclerosis Risk in Communities (ARIC) Study, a prospective study of 15,800 middle-aged men and women, measured AT III in its baseline examination. AT III levels were significantly higher in women than men, and in blacks than whites. AT III decreased with age in men but increased with age in women. In age- and race-adjusted analyses, AT III was positively associated with smoking, HDL-cholesterol, triglycerides (men only), and in women, with diabetes and lipoprotein(a). AT III was negatively associated with educational level, body mass index in men, and use of female hormones in women. Most of these associations were confirmed in multivariate analysis. These correlations between AT III and other risk factors must be considered when evaluating AT III as a risk factor for venous or arterial thrombosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7878631

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  The Laboratory of Hypercoagulability: A Review of Present-Day Techniques.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-07       Impact factor: 2.300

2.  The coagulofibrinolytic state of patients with primary varicose veins of the lower legs.

Authors:  M Ikeda; J Kambayashi; S Iwamoto; N Shinoki; T Nakamura; T Shibuya; T Kawasaki; M Monden
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

3.  The Association of Anticoagulant Protein Concentrations with Acute Myocardial Infarction in the Thromholysis in Myocardial Infarction Phase II (TIMI II) Trial.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998       Impact factor: 2.300

4.  Functional consequences of the prothrombotic SERPINC1 rs2227589 polymorphism on antithrombin levels.

Authors:  Ana I Antón; Raúl Teruel; Javier Corral; Antonia Miñano; Irene Martínez-Martínez; Adriana Ordóñez; Vicente Vicente; Beatriz Sánchez-Vega
Journal:  Haematologica       Date:  2009-02-19       Impact factor: 9.941

Review 5.  Pathophysiological Aspects of Aging in Venous Thromboembolism: An Update.

Authors:  Dimitra Akrivou; Garifallia Perlepe; Paraskevi Kirgou; Konstantinos I Gourgoulianis; Foteini Malli
Journal:  Medicina (Kaunas)       Date:  2022-08-10       Impact factor: 2.948

6.  Identification of antithrombin-modulating genes. Role of LARGE, a gene encoding a bifunctional glycosyltransferase, in the secretion of proteins?

Authors:  María Eugenia de la Morena-Barrio; Alfonso Buil; Ana Isabel Antón; Irene Martínez-Martínez; Antonia Miñano; Ricardo Gutiérrez-Gallego; José Navarro-Fernández; Sonia Aguila; Juan Carlos Souto; Vicente Vicente; José Manuel Soria; Javier Corral
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

7.  Identification of Regulatory Mutations in SERPINC1 Affecting Vitamin D Response Elements Associated with Antithrombin Deficiency.

Authors:  Mara Toderici; María Eugenia de la Morena-Barrio; José Padilla; Antonia Miñano; Ana Isabel Antón; Juan Antonio Iniesta; María Teresa Herranz; Nuria Fernández; Vicente Vicente; Javier Corral
Journal:  PLoS One       Date:  2016-03-22       Impact factor: 3.240

8.  Hemostasis in elderly patients with human immunodeficiency virus (HIV) infection-Cross-sectional study.

Authors:  Marilza Campos de Magalhães; Juan Camilo Sánchez-Arcila; Ana Carolina de Brito Lyra; Luiz Felipe Boufleur Long; Isabelle Vasconcellos de Souza; Fernando Raphael de Almeida Ferry; Adilson José de Almeida; Soniza Vieira Alves-Leon
Journal:  PLoS One       Date:  2020-02-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.